title: Immune status and uptake of antiretroviral interventions to prevent mother-to-child transmission of HIV-1 in Africa.
abstract: The aim of this study performed in Abidjan, Côte d'Ivoire, was to describe the distribution of CD4+ T-cell lymphocytes (CD4) in HIV-1-infected (HIV+) pregnant women diagnosed during prenatal voluntary counseling and testing and to assess whether HIV-related immunodeficiency influenced the acceptance of an antiretroviral (ARV) package (zidovudine beginning at 36 weeks of amenorrhea plus intrapartum nevirapine) to prevent mother-to-child transmission. Between April and June 2002, a CD4 count was systematically performed in all HIV+ women (n=221) in 5 antenatal clinics carrying out voluntary counseling and testing. No difference in CD4 count was found in HIV+ women who did not return for their test result (n=50) and those who were informed of their positive serostatus (n=171) (median CD4 count: 389/mm3 vs. 420/mm3; P=0.19). We also found a lack of difference in CD4 count in those who accepted ARV (n=72) and those who did not but knew their HIV status (n=99) (median CD4 count: 405/mm3 vs. 425/mm3; P=0.47). The overall uptake of the intervention (31.9%) appeared to be independent of the maternal immune status.
authors.affiliation: Projet ANRS 1201/1202 Ditrame Plus and CeDReS, Programme PACCI, Abidjan, Côte d'Ivoire, France. ekouevi@aviso.ci
authors.forename: Didier K
authors.initials: DK
authors.lastname: Ekouevi
authors.forename: François
authors.initials: F
authors.lastname: Rouet
authors.forename: Renaud
authors.initials: R
authors.lastname: Becquet
authors.forename: André
authors.initials: A
authors.lastname: Inwoley
authors.forename: Ida
authors.initials: I
authors.lastname: Viho
authors.forename: Besigin
authors.initials: B
authors.lastname: Tonwe-Gold
authors.forename: Laurence
authors.initials: L
authors.lastname: Bequet
authors.forename: François
authors.initials: F
authors.lastname: Dabis
authors.forename: Valériane
authors.initials: V
authors.lastname: Leroy
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D018791:CD4 Lymphocyte Count; D007560:Cote d'Ivoire; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control / Q000635:transmission*; D015497:HIV-1; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D019829:Nevirapine / Q000008:administration & dosage; D010342:Patient Acceptance of Health Care; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000276:immunology*; D015215:Zidovudine / Q000008:administration & dosage
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine; D019829:Nevirapine